1. Home
  2. THH vs BIVI Comparison

THH vs BIVI Comparison

Compare THH & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TryHard Holdings Limited Ordinary Shares

THH

TryHard Holdings Limited Ordinary Shares

N/A

Current Price

$1.32

Market Cap

11.1M

Sector

N/A

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

N/A

Current Price

$1.34

Market Cap

12.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
THH
BIVI
Founded
2013
2013
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
12.4M
IPO Year
2025
2013

Fundamental Metrics

Financial Performance
Metric
THH
BIVI
Price
$1.32
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $5.26
AVG Volume (30 Days)
15.0K
★ 839.8K
Earning Date
11-21-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 74.83
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$305.05
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.82
52 Week High
$56.26
$3.79

Technical Indicators

Market Signals
Indicator
THH
BIVI
Relative Strength Index (RSI) 43.22 47.50
Support Level $0.27 $1.15
Resistance Level $1.50 $1.42
Average True Range (ATR) 0.11 0.22
MACD 0.01 0.01
Stochastic Oscillator 22.92 14.48

Price Performance

Historical Comparison
THH
BIVI

About THH TryHard Holdings Limited Ordinary Shares

Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Share on Social Networks: